IC
IRLA

Iconiq Capital’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Iconiq Capital’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-155
Closed -$41K – 62
2022
Q3 		$41K Buy
+155
New +$59K ﹤0.01% 63
2021
Q4 		– Sell
-92
Closed -$1.69M – 78
2021
Q3 		$1.69M Hold
92
– – 0.01% 51
2021
Q2 		$976K Hold
92
– – 0.01% 50
2021
Q1 		$664K Buy
+92
New +$662K 0.01% 44

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Iconiq Capital's IRLA Position: Q4 2022 in Review

Iconiq Capital sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2022, closing a stake of 155 shares — an estimated $41K sold.

Iconiq Capital first reported a position in IRLA in Q1 2021 and held it in 4 quarters. The position peaked at $1.69M in Q3 2021. 48 funds tracked by Wall St. Rank hold IRLA as of Q4 2022.

  • Iconiq Capital reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Iconiq Capital sold 155 IRulya Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $41K.
  • Iconiq Capital first reported a position in IRulya Therapeutics Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Iconiq Capital's IRulya Therapeutics Inc. Common Stock position peaked at $1.69M in Q3 2021.
  • 48 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2022.

Based on Iconiq Capital's 13F filing for Q4 2022, filed 13 Feb 2023.